Compare Plby Group Inc (PLBY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Tango Therapeutics Inc. — how do they compare? Plby Group Inc trades at $0.97 (market cap $122.20M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 30.7× Plby Group Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Tango Therapeutics Inc. for 0 Days on average.
| PLBY | TNGX | |
|---|---|---|
Market Cap | $122.20M | $3.75B |
Volume | 540,321 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $32.90 |
52-Week Low | $0.98 | $7.50 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $267.79M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $0.99, down 0.32% with a bearish technical signal. The company shows improving fundamentals with revenue stabilizing around $121M in 2025 and narrowing losses from -$278M in 2022 to -$13M. Recent Q2 2026 earnings beat expectations with positive operating cash flow. Analyst sentiment remains strong with 75% buy ratings, while technical indicators show oversold conditions with RSI at neutral levels.
The outlook suggests cautious optimism as PLBY demonstrates operational improvement and debt reduction, though negative shareholder equity and high P/E ratio of 51 present valuation concerns. Key risks include persistent negative equity and competitive pressures in the consumer discretionary space.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
